{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06369298",
            "orgStudyIdInfo": {
                "id": "JK07.2.01"
            },
            "organization": {
                "fullName": "Salubris Biotherapeutics Inc",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of JK07 in Patients With Chronic Heart Failure",
            "officialTitle": "A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of JK07 in Adults With Chronic Heart Failure (RENEU-HF)",
            "acronym": "RENEU-HF",
            "therapeuticArea": [
                "Cardiovascular"
            ],
            "study": "study-of-in-patients-with-chronic-heart-failure"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-03-28",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-06-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-04-12",
            "studyFirstSubmitQcDate": "2024-04-12",
            "studyFirstPostDateStruct": {
                "date": "2024-04-16",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-29",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-30",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Salubris Biotherapeutics Inc",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure.\n\nThere will be 2 cohorts in this study:\n\nCohort 1: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) of \u2264 40%.\n\nCohort 2: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) \\> 40% and \u2264 65%.\n\nParticipants in both cohorts will be randomized into either low dose JK07, high dose JK07 or placebo. Participants will have a 2:1 chance of receiving JK07 versus placebo."
        },
        "conditionsModule": {
            "conditions": [
                "Heart Failure With Reduced Ejection Fraction",
                "Heart Failure With Preserved Ejection Fraction"
            ],
            "keywords": [
                "Heart Failure",
                "Heart Failure with Reduced Ejection Fraction",
                "Heart Failure with Preserved Ejection Fraction",
                "Heart Failure NYHA Class III",
                "Heart Failure NYHA Class II",
                "Heart Failure with Atrial Fibrillation/Flutter",
                "HFrEF",
                "HFpEF",
                "Neuregulin 1",
                "NRG-1",
                "HER3",
                "HER4",
                "ErbB3",
                "ErbB4",
                "Systolic Heart Failure",
                "Diastolic Heart Failure",
                "Atrial Fibrillation",
                "Atrial Flutter"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 282,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "JK07 low dose",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "JK07 administered by intravenous (IV) infusion",
                    "interventionNames": [
                        "Drug: JK07"
                    ]
                },
                {
                    "label": "JK07 high dose",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "JK07 administered by intravenous (IV) infusion",
                    "interventionNames": [
                        "Drug: JK07"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Placebo administered by intravenous (IV) infusion",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "JK07",
                    "description": "JK07 is a fully human anti-human epidermal growth factor receptor 3 (also known as ErbB3 or HER3) antibody fused with the epidermal growth factor (EGF)-domain of Neuregulin (NRG)-1b protein.",
                    "armGroupLabels": [
                        "JK07 high dose",
                        "JK07 low dose"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "0.9% sodium chloride",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Safety - Cohort 1",
                    "description": "Incidence and severity of treatment emergent adverse events",
                    "timeFrame": "Study entry through week 52"
                },
                {
                    "measure": "Efficacy - Cohort 1",
                    "description": "Change in LVEF measured by 2D-TTE",
                    "timeFrame": "Baseline through week 26"
                },
                {
                    "measure": "Safety - Cohort 2",
                    "description": "Incidence and severity of treatment emergent adverse events",
                    "timeFrame": "Study entry through week 52"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Participants with New York Heart Association (NYHA) Class II-III.\n* Cohort 1 - Left Ventricular Ejection Fraction (LVEF) \u2264 40%.\n* Cohort 2 - Left Ventricular Ejection Fraction (LVEF) \\>40% and \u2264 65%, elevated N-terminal pro B-type natriuretic peptide (NT-proBNP) \u2265 600pg/mL and atrial fibrillation/flutter.\n* Stable heart failure and on optimal medical therapy.\n* Screening hemoglobin \u2265 9.0 g/dL.\n\nExclusion Criteria:\n\n* Uncontrolled hypertension.\n* Sustained systolic Blood Pressure (BP) \\< 90 mmHg and/or diastolic BP \\< 50 mmHg on at least 3 consecutive readings.\n* Heart failure due to hypertrophic cardiomyopathy, restrictive and/or infiltrative cardiomyopathy, arrhythmogenic right ventricular dysplasia, Fabry disease, or Noonan syndrome with LV hypertrophy or a positive serum immunofixation result.\n* Diagnosis of stress-induced (Takotsubo) cardiomyopathy, myocarditis, or peripartum cardiomyopathy.\n* Diagnosis of chemotherapy- or radiation-induced cardiomyopathy.\n* Diagnosed with stroke or Transient Ischemic Attack (TIA) within 12 weeks of screening.\n* History of syncope within the last 12 weeks prior to screening or sustained ventricular tachycardia without an implantable cardioverter-defibrillator.\n* Moderate or severe aortic and/or mitral valve stenosis.\n* Medically documented unstable angina, acute coronary syndrome (e.g., myocardial infarction, troponin-positive with symptoms of angina or unstable angina) within the last 8 weeks prior to start of screening.\n* Medically documented ST-elevation myocardial infarction within 12 weeks of screening.\n* Any narrow complex tachycardia (inclusive of Atrial Fibrillation (AF) or atrial flutter) with a resting ventricular rate \\> 110 beats per minute at screening.\n* For participants with a history of Atrial Fibrillation (AF) or atrial flutter, and a CHA2DS2-VASc score of \u2265 2 in men or \u2265 3 in women or per local guidelines, anticoagulation via non-vitamin K oral anticoagulants or warfarin is required. Percutaneous occlusion of the left atrial appendage alone is not adequate.\n* AF ablation within the last 12 weeks or planned during the study duration.\n* Symptomatic bradycardia or second (Mobitz Type II)- or third-degree heart block without a pacemaker.\n* Cardiac surgery, coronary artery revascularization or indication for coronary artery revascularization, percutaneous coronary intervention, valve repair/replacement or valvuloplasty within 12 weeks prior to screening.\n* Implantation of a Cardiac Resynchronization Therapy (CRT) device within 12 weeks prior to screening, or intent to implant a CRT device during the course of the study.\n* Previous cardiac transplantation, or any use of mechanical circulatory support or similar device, or implantation expected after randomization.\n* Receiving mechanical hemodynamic support or invasive mechanical ventilation within the last 8 weeks prior to screening.\n* Receiving Intravenous (IV) inotropes or IV vasopressors within the last 8 weeks prior to screening.\n* Receiving IV vasodilators within the last 4 weeks prior to screening.\n* Receiving noninvasive mechanical ventilation within the last 4 weeks prior to screening. The use of noninvasive ventilation for sleep disordered breathing is permitted.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "85 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Amanda McEwen",
                    "role": "CONTACT",
                    "phone": "888-521-8961",
                    "email": "Info@SalubrisBio.com"
                },
                {
                    "name": "Ashleigh Chasteen",
                    "role": "CONTACT",
                    "phone": "888-521-8961",
                    "email": "Info@Salubrisbio.com"
                }
            ],
            "locations": [
                {
                    "facility": "Southern California Heart Specialists",
                    "status": "RECRUITING",
                    "city": "Pasadena",
                    "state": "California",
                    "zip": "91105",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Gregory Giesler",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.14778,
                        "lon": -118.14452
                    }
                },
                {
                    "facility": "New Generation of Medical Research",
                    "status": "RECRUITING",
                    "city": "Hialeah",
                    "state": "Florida",
                    "zip": "33016",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Karelia Ruiz",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.8576,
                        "lon": -80.27811
                    }
                },
                {
                    "facility": "Louisiana Heart Center",
                    "status": "RECRUITING",
                    "city": "Covington",
                    "state": "Louisiana",
                    "zip": "70433",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Bruce Iteld, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.47549,
                        "lon": -90.10042
                    }
                },
                {
                    "facility": "Cardiology and Vascular Associates",
                    "status": "RECRUITING",
                    "city": "Bloomfield Hills",
                    "state": "Michigan",
                    "zip": "48304",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Kirit Patel",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.58364,
                        "lon": -83.24549
                    }
                },
                {
                    "facility": "St. Louis Heart and Vascular Cardiology",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63136",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Harvey Serota",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "Southwest Family Medicine",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75235",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Chriistte Dharma",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000006333",
                    "term": "Heart Failure"
                }
            ],
            "ancestors": [
                {
                    "id": "D000006331",
                    "term": "Heart Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9421",
                    "name": "Heart Failure",
                    "asFound": "Heart Failure",
                    "relevance": "HIGH"
                },
                {
                    "id": "M27579",
                    "name": "Heart Failure, Systolic",
                    "relevance": "LOW"
                },
                {
                    "id": "M4586",
                    "name": "Atrial Fibrillation",
                    "relevance": "LOW"
                },
                {
                    "id": "M4587",
                    "name": "Atrial Flutter",
                    "relevance": "LOW"
                },
                {
                    "id": "M27580",
                    "name": "Heart Failure, Diastolic",
                    "relevance": "LOW"
                },
                {
                    "id": "M27583",
                    "name": "Systolic Murmurs",
                    "relevance": "LOW"
                },
                {
                    "id": "M9419",
                    "name": "Heart Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M11900",
                    "name": "Mitogens",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}